Sugi Predict

Sugi Predict / Targets / PDE5A

PDE5A

cGMP-specific 3',5'-cyclic phosphodiesterase · O76074 · PDE5A on Sugi Atlas →

140,411 patent compounds predicted against PDE5A, 80,485 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Lodenafil Lodenafil (SCHEMBL1058) 1.00 20/20
Vardenafil Vardenafil (SCHEMBL5441) 1.00 20/20
SCHEMBL5517 SCHEMBL5517 1.00 20/20
SCHEMBL5530 SCHEMBL5530 1.00 20/20
SCHEMBL5537 SCHEMBL5537 1.00 20/20
Vardenafil Vardenafil (SCHEMBL5685) 1.00 20/20
Vardenafil Vardenafil (SCHEMBL5772) 1.00 20/20
Sildenafil Sildenafil (SCHEMBL33982) 1.00 20/20
SCHEMBL119186 SCHEMBL119186 1.00 20/20
SCHEMBL119755 SCHEMBL119755 1.00 20/20
Gisadenafil Gisadenafil (SCHEMBL120995) 1.00 20/20
SCHEMBL1190 SCHEMBL1190 0.90 20/20
SCHEMBL146830 SCHEMBL146830 0.90 20/20
SCHEMBL997 SCHEMBL997 0.89 20/20
SCHEMBL13694 SCHEMBL13694 0.87 20/20
SCHEMBL1423 SCHEMBL1423 0.86 20/20
SCHEMBL1251 SCHEMBL1251 0.85 20/20
SCHEMBL1238 SCHEMBL1238 0.85 20/20
SCHEMBL1516 SCHEMBL1516 0.84 20/20
SCHEMBL5606 SCHEMBL5606 0.81 20/20

Clinical trials — most relevant to PDE5A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis PHASE4COMPLETED
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study PHASE4COMPLETED
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes PHASE4COMPLETED
Bosentan in Treatment of Pulmonary Arterial Hypertension PHASE4COMPLETED
Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure PHASE4WITHDRAWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer PHASE3RECRUITING
Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate PHASE2/PHASE3RECRUITING
Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm PHASE3WITHDRAWN
Clinical Trial Using Topically Applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction PHASE3COMPLETED
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage PHASE3NOT_YET_RECRUITING
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial PHASE2COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
Effect of Tadalafil on Cerebral Large Arteries in Stroke PHASE2COMPLETED
Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study PHASE2UNKNOWN
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH) PHASE2RECRUITING
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects PHASE1COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects PHASE1COMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Endurance Performance at Altitude nanCOMPLETED
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones nanCOMPLETED
Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDE5A binder may also engage these)

ProteinNameSimilarity
O54735 — 1.000 O54735 →
O77746 — 1.000 O77746 →
Q28156 — 1.000 Q28156 →
Q8CG03 — 1.000 Q8CG03 →
Q1KKS3 — 0.998 Q1KKS3 →
B4LVU6 — 0.996 B4LVU6 →
PDE11A Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A 0.993 landscape →
P33726 — 0.992 P33726 →
B3LVW5 — 0.992 B3LVW5 →
P23439 — 0.991 P23439 →
B3P3K2 — 0.991 B3P3K2 →
B4K9L4 — 0.990 B4K9L4 →
Q91ZQ1 — 0.990 Q91ZQ1 →
Q8VID6 — 0.990 Q8VID6 →
P0C1Q2 — 0.990 P0C1Q2 →
Q298P4 — 0.990 Q298P4 →
Q9VFI9 — 0.989 Q9VFI9 →
B4HEM4 — 0.989 B4HEM4 →
PDE6A Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha 0.988 landscape →
P16586 — 0.988 P16586 →
B4NAL6 — 0.988 B4NAL6 →
B4PSS5 — 0.988 B4PSS5 →
Q28263 — 0.987 Q28263 →
P23440 — 0.987 P23440 →
PDE6B Rod cGMP-specific 3',5'-cyclic phosphodiester 0.987 landscape →
PDE2A cGMP-dependent 3',5'-cyclic phosphodiesterase 0.987 landscape →
B4JXX2 — 0.987 B4JXX2 →
PDE6C Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' 0.987 landscape →
P52731 — 0.986 P52731 →
B4QZU1 — 0.986 B4QZU1 →